Elevation Oncology reported developments tied to its oncology drug-development business, including antibody-drug conjugate programs for solid tumors. Company updates covered EO-1022, a HER3 ADC designed with seribantumab, an MMAE payload and glycan site-specific conjugation, as well as the discontinued EO-3021 Claudin 18.2 ADC program for gastric and gastroesophageal junction cancers.
Recurring news also included financial results, research presentations, program prioritization, workforce restructuring, strategic alternatives, material agreements, governance matters and capital-structure developments. Later corporate-status disclosures documented the company’s acquisition process, Nasdaq delisting and termination of Exchange Act registration.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.